Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 TrialTORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in dif ...

Core Viewpoint - Quantum BioPharma Ltd. has completed dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302, aimed at treating Multiple Sclerosis, which is a significant step towards submitting an IND application to the US FDA [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, including Multiple Sclerosis [3]. - The company is advancing its lead compound, Lucid-MS, which is a patented new chemical entity designed to prevent and reverse myelin degradation, a key mechanism in Multiple Sclerosis [3]. Development Progress - The completion of toxicity studies for Lucid-21-302 brings the company closer to initiating a Phase 2 trial for Multiple Sclerosis [2]. - The company plans to submit the IND application for Lucid-21-302 before the end of the year [2]. Strategic Investments - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition, which is involved in the OTC version of its product unbuzzd™. The agreement includes a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [3]. - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3].